Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PLEC | Q15149 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24274961 | 0.83 | MAPT (0.68) | MAPTHPGDL3MBTL1MEN1KMT2A | |
| SCHEMBL26085708 | 0.80 | CFD (0.53) | MAPTLIPGHPGDL3MBTL1LMNA | |
| SCHEMBL13830817 | 0.80 | CA1 (0.62) | MAPTHIF1AHPGDMEN1KMT2A | |
| SCHEMBL10055008 | 0.79 | MAPT (0.53) | MAPTHIF1AHPGDL3MBTL1MEN1 | |
| SCHEMBL902105 | 0.78 | LIPG (0.50) | MAPTLIPGMEN1KMT2AALDH1A1 | |
| SCHEMBL30949224 | 0.78 | LIPG (0.50) | MAPTLIPGMEN1KMT2AALDH1A1 | |
| SCHEMBL30949223 | 0.78 | LIPG (0.50) | MAPTLIPGMEN1KMT2AALDH1A1 | |
| SCHEMBL28433585 | 0.77 | MAPT (0.63) | MAPTLIPGL3MBTL1MEN1KMT2A | |
| SCHEMBL13830752 | 0.76 | EGFR (0.62) | HIF1AHPGDALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL13287109 | 0.76 | LIPG (0.48) | HIF1ALIPGPKMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118453643-A | Antioxidant high polymer hydrogel and preparation method and application thereof | 哈尔滨医科大学 | 2024-08-09 | — | — | CN | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| CN-111848668-B | Pyridinylamino IVB group binuclear metal complex and preparation and application thereof | 万华化学集团股份有限公司 | 2023-03-03 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| CN-111848668-A | Pyridinylamino IVB group binuclear metal complex and preparation and application thereof | 万华化学集团股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
| US-20140161729-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2012154213-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY (US) | 2012-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | MAPT 4627/4885HIF1A 2197/4885LIPG 3777/4885 |
| US-20140161729-A1 | COFLUORONS AND METHODS OF MAKING AND USING THEM | TNFSF11, CD14, TNFRSF1A | MAPT 418/4885HIF1A 2817/4885LIPG 2627/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | MAPT 4627/4885HIF1A 2197/4885LIPG 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.